<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004304.pub2" GROUP_ID="EPILEPSY" ID="380302102909313652" MERGED_FROM="" MODIFIED="2009-08-11 22:10:58 +0200" MODIFIED_BY="Rachael Kelly" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-08-07 20:52:48 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0054" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.1">
<COVER_SHEET MODIFIED="2009-08-11 22:10:58 +0200" MODIFIED_BY="Rachael Kelly">
<TITLE>Vitamins for epilepsy</TITLE>
<CONTACT MODIFIED="2009-08-11 22:10:58 +0200" MODIFIED_BY="Rachael Kelly"><PERSON ID="13564" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lakshmi Narasimhan</FIRST_NAME><LAST_NAME>Ranganathan</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>lakshmineuro@gmail.com</EMAIL_1><EMAIL_2>ln1@vsnl.com</EMAIL_2><URL>www.medigates.com</URL><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Kilpauk Medical College</ORGANISATION><CITY>Chennai</CITY><ZIP>600014</ZIP><REGION>Tamil Nadu</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 44 2811 5294</PHONE_1><PHONE_2>+91 94443  80409</PHONE_2><FAX_1>+91 44 242 3835</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-08-11 22:10:58 +0200" MODIFIED_BY="Rachael Kelly"><PERSON ID="13564" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lakshmi Narasimhan</FIRST_NAME><LAST_NAME>Ranganathan</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>lakshmineuro@gmail.com</EMAIL_1><EMAIL_2>ln1@vsnl.com</EMAIL_2><URL>www.medigates.com</URL><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Kilpauk Medical College</ORGANISATION><CITY>Chennai</CITY><ZIP>600014</ZIP><REGION>Tamil Nadu</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 44 2811 5294</PHONE_1><PHONE_2>+91 94443  80409</PHONE_2><FAX_1>+91 44 242 3835</FAX_1></ADDRESS></PERSON><PERSON ID="4928" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sridharan</FIRST_NAME><LAST_NAME>Ramaratnam</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>rsridharan@vsnl.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Apollo Hospitals</ORGANISATION><ADDRESS_1>21 Greams Lane</ADDRESS_1><ADDRESS_2>Off Greams Road</ADDRESS_2><CITY>Chennai</CITY><ZIP>600006</ZIP><REGION>Tamil Nadu</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 44 2829 6559</PHONE_1><PHONE_2>+91 44 2814 3365</PHONE_2><FAX_1>+91 44 2829 4429</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-08-07 20:48:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 2/21/07&lt;/p&gt;" NOTES_MODIFIED="2009-08-07 20:48:18 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="12" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="12" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="5" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2009-08-07 20:47:48 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-07 20:47:48 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Copyedits made at editorial base.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-08-07 20:47:28 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-07 20:47:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-03 10:39:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="12" YEAR="2006"/>
<DESCRIPTION>
<P>We re-ran our searches on 22nd December 2006; no new studies were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-07 20:52:48 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-03 10:35:38 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-03 10:35:36 +0100" MODIFIED_BY="[Empty name]">Vitamins for epilepsy</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-03 10:35:38 +0100" MODIFIED_BY="[Empty name]">
<P>No evidence that folic acid, thiamine, vitamin D or vitamin E improve seizure control or prevent side effects for people with epilepsy.</P>
<P>Antiepileptic drugs stop seizures for 70% of people with epilepsy and cause a number of side effects. This review investigated if vitamins improve seizure control or prevent side effects such as gum swelling, memory problems, osteoporosis, problems with blood cell formation and effects on peripheral nerves. The studies reviewed investigated the use of folic acid, thiamine, vitamin D and vitamin E and were of poor methodological quality. There is no conclusive evidence that vitamins improve seizure control or prevent side effects for people with epilepsy. Further studies are needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-17 16:54:35 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Vitamins have been reported to be effective in controlling certain types of seizures and to prevent some of the harmful effects of antiepileptic drugs (AEDs). In this review we will summarize evidence from randomized controlled trials.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess if vitamins improve seizure control, reduce adverse effects of AEDs or improve the quality of life in people with epilepsy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-17 16:54:35 +0100" MODIFIED_BY="[Empty name]">
<P>We searched MEDLINE from 1966 to October 2006, the Cochrane Epilepsy Group Specialized Register (December 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The</I> <I>Cochrane</I> <I>Library</I> Issue 4, 2006), and cross-references from identified studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized or quasi-randomized studies investigating the effects of one or more vitamins given alone or in addition to AEDs to people of any age with any type of epilepsy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Both review authors assessed the trials for inclusion and extracted the data. Outcomes assessed included seizure frequency, gingival hyperplasia, neuropathy, changes in bone mineral content, serum calcium, alkaline phosphatase, hemogram, serum levels of AEDs, neuropsychological and quality of life outcomes. Primary analyses were by intention to treat.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Fifteen studies met our inclusion criteria and were of poor methodological quality. None described randomization methods and most enrolled small numbers of participants. Nine studies (331 participants) investigated folic acid. Two studies (75 participants) found no effect for the outcome 50% or greater reduction in seizure frequency (OR 0.96; 95% CI 0.32 to 2.29). Also, no evidence was found for an effect on gingival health, intelligence, behavior, mental health or personality, or measures of red blood volume and hemoglobin content. Folic acid was not associated with any consistent changes in serum phenytoin or phenobarbitone levels or improvement in the mean motor conduction velocities of peripheral nerves. One small study (72 participants) found that thiamine improves neuropsychological functions related to psychomotor speed, visuospatial abilities, selective attention and verbal abstracting ability. One study (226 participants) found a significantly higher bone mineral content (BMC) among patients with epilepsy taking AEDs with vitamin D supplementation compared to controls who were not given supplementation (OR 3.6; 95% CI 2.48 to 4.72; p &lt; 0.00001). The studies found no significant effects on serum calcium, alkaline phosphatase or general well-being. One small study (24 participants) found a significant decrease in seizure frequency in those treated with vitamin E compared to placebo (p = 0.00005; Peto OR 26.73; 95% CI 5.46 to 130.92).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>In view of methodological deficiencies and limited number of individual studies, we have found no reliable evidence to support the routine use of vitamins in patients with epilepsy. Further trials are needed, especially to assess the utility of vitamin D supplementation to prevent osteomalacia and the role of vitamin E on seizures and thiamine in improving cognitive functions.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-07 20:52:48 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Epilepsy is a common neurological condition, with an estimated annual incidence of 50 per 100,000 and prevalence of 5 to 10 per 1000 in the developed world (<LINK REF="REF-Sander-1996" TYPE="REFERENCE">Sander 1996</LINK>). Between two and three per cent of the population will be given a diagnosis of epilepsy at some time in their lives (<LINK REF="REF-Hauser-1993" TYPE="REFERENCE">Hauser 1993</LINK>), the majority of whom (70%) will go into remission. Up to 30% will continue to have seizures (that is, become drug-resistant) despite treatment with adequate doses of AEDs, and hence there is a constant search for newer modes of treatment. Moreover the commonly used AEDs have several adverse effects such as gingival hyperplasia (swelling of gums), gastrointestinal disturbances (nausea, vomiting), osteoporosis (abnormal rarefaction of bones), osteomalacia (inadequate or delayed mineralization of bone), bone marrow toxicity (interference with production of blood cells), teratogenicity (birth defects), hepatotoxicity (adverse effects on liver function), renal toxicity (adverse effects on kidney), neurological symptoms (ataxia, dizziness, diplopia, somnolence), cognitive, mood and behavioral effects, endocrine dysfunction (disturbances of hormone levels) as well as allergic skin rashes, including toxic epidermal necrolysis or Steven Johnson syndrome (<LINK REF="REF-Holland-2001" TYPE="REFERENCE">Holland 2001</LINK>).</P>
<P>Vitamins is a general term for a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body. They may be water-soluble (vitamin B complex and vitamin C) or fat-soluble (vitamins A, D, E and K) (<LINK REF="REF-Dorland-1994" TYPE="REFERENCE">Dorland 1994</LINK>).</P>
<P>Vitamins are of benefit in certain types of epilepsies. For example, the classic form of pyridoxine (vitamin B6) dependent epilepsy is a relentless seizure disorder that begins in the first week of life, or even in utero. The seizures are poorly controlled if at all by traditional antiepileptic drugs. The diagnosis is based on the clinical and electroencephalogram response to pyridoxine, which is usually rapid (<LINK REF="REF-Gupta-2001" TYPE="REFERENCE">Gupta 2001</LINK>). Pyridoxine is also considered an antidote for INH (a drug used to treat tuberculosis) induced seizures and has been tried for control of recurrent seizures (<LINK REF="STD-Jiao-1997" TYPE="STUDY">Jiao 1997</LINK>) and for febrile convulsions (<LINK REF="REF-Rantala-1997" TYPE="REFERENCE">Rantala 1997</LINK>). Other vitamins such as vitamin D, folic acid and vitamin E have also been tried as add-on to antiepileptic drugs (<LINK REF="STD-Christiansen-1974" TYPE="STUDY">Christiansen 1974</LINK>; <LINK REF="STD-Raju-1994" TYPE="STUDY">Raju 1994</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>) to improve seizure control. </P>
<P>Vitamins may prevent harmful effects of antiepileptic drugs such as teratogenicity, anemia, osteomalacia, bleeding tendencies and peripheral neuropathies. There appears to be a two to three fold increase in congenital malformations among babies born to women with epilepsy compared to the general population (<LINK REF="REF-El-Sayed-1998" TYPE="REFERENCE">El Sayed 1998</LINK>). The most common major malformations described have included congenital heart disease, cleft lip and/or palate, limb defects, genitourinary malformations and neural tube defects. Neural tube defects have been specifically associated with sodium valproate (<LINK REF="REF-Lindhout-1986" TYPE="REFERENCE">Lindhout 1986</LINK>) and carbamazepine (<LINK REF="REF-Rosa-1991" TYPE="REFERENCE">Rosa 1991</LINK>). Periconceptional supplementation with folate and/or multivitamins, has been found useful for preventing neural tube defects in women without epilepsy (<LINK REF="REF-Lumley-2001" TYPE="REFERENCE">Lumley 2001</LINK>) and is likely to prevent neural tube defects in pregnant women on antiepileptic drugs. </P>
<P>Hypocalcemia, alterations in bone mineral density and osteomalacia may be seen as a result of phenytoin-induced alterations in vitamin D metabolism. (<LINK REF="REF-Bazil-2003" TYPE="REFERENCE">Bazil 2003</LINK>) and may be preventable by vitamin D supplementation. However, long-term vitamin D supplementation may be associated with hypervitaminosis D and caution is needed (<LINK REF="REF-Marriott-1997" TYPE="REFERENCE">Marriott 1997</LINK>). </P>
<P>Gingival hyperplasia is a common side effect of phenytoin therapy and there are reports regarding the use of folic acid in the prevention of gingival hyperplasia (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>). The effect of folic acid has also been investigated for improving the intelligence (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>), behavior (<LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>) and preventing peripheral neuropathy in people with epilepsy taking antiepileptic drugs (<LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>).</P>
<P>There have been no systematic studies on the use of vitamins in patients with epilepsy until now. Hence, we have planned to do a systematic review of the role of administration of vitamins in patients with epilepsy particularly focusing on the role of vitamins in improving seizure control, prevention/reduction of major adverse effects of AEDs, such as teratogenicity, osteoporosis, osteomalacia, gingival hyperplasia, neuropathy, cognitive deficit and hematological effects.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine whether for people with epilepsy, the use of vitamins improves seizure control or prevents/reduces adverse effects such as osteoporosis, osteomalacia, gingival hyperplasia, cognitive deficits, hematological and other side effects. To also investigate any adverse effects associated with vitamin therapy. This review does not address the provision of nutritional advice, counseling, dietary modification or dietary fortification. </P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-04 14:49:40 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>(1) Randomized controlled trials using an adequate method of allocation concealment, and those that are quasi-randomized (eg. allocation by day of the week). <BR/>(2) Single or double blind or unblinded.<BR/>(3) Parallel group or crossover studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with epilepsy or epilepsy syndromes of all types (<LINK REF="REF-Commission-1989" TYPE="REFERENCE">Commission 1989</LINK>), of any age and either gender.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Treatment group will receive one or more vitamins alone or as add-on to AEDs.<BR/>Controls receive placebo, no treatment or some other treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>(1) Seizure freedom - 50% or greater reduction in seizure frequency.<BR/>(2) Improved quality of life (QOL) if assessed by validated scales.<BR/>(3) Reduction in adverse effects/side effects:<BR/>(a) hematological - effects if any on hematocrit or coagulation parameters;<BR/>(b) osteoporosis - alterations in bone mineral density, or occurrence of fractures;<BR/>(c) osteomalacia - clinical and radiological diagnosis or low levels of vitamin D;<BR/>(d) neurological - clinical/electrophysiological evidence of peripheral nerve dysfunction (Yes/No);<BR/>(e) gingival hyperplasia - significant reduction in gingival hyperplasia (Yes/No);<BR/>(f) cognitive deficit - improvement in memory and intelligence assessed by standardized validated scales;<BR/>(g) adverse effects of vitamin therapy - occurrence of hypervitaminosis A, D and E.</P>
<P>Teratogenesis associated with AEDs is a subject of another Cochrane review (<LINK REF="REF-Adab-2004" TYPE="REFERENCE">Adab 2004</LINK>) and hence was not included in this review.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-04 14:49:40 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-08-04 14:49:40 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases:</P>
<P>(1) Cochrane Epilepsy Group Specialized Register (22 December 2006);</P>
<P>(2) The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 4, 2006) using the search strategy outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>;</P>
<P>(3) MEDLINE (Ovid, 1966 to October 2006) using the search strategy outlined in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-08-04 14:49:16 +0100" MODIFIED_BY="[Empty name]">
<P>We looked for cross-references from identified publications. Colleagues and experts in the field were asked if they knew of any relevant studies we may have missed.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two review authors (LNR, SR) independently assessed trials for inclusion with disagreements resolved by mutual discussion.</P>
<P>The same two review authors independently extracted the following data, and again any differences of opinion were resolved by mutual discussion.</P>
<P>(1) Study Methods:<BR/>(a) design (eg. parallel or cross-over design);<BR/>(b) randomization method (allocation concealment and list generation);<BR/>(c) blinding method;<BR/>(d) losses to follow-up.</P>
<P>(2) Participants:<BR/>(a) number (total/per group);<BR/>(b) age and sex distribution;<BR/>(c) seizure type and epilepsy syndrome;<BR/>(d) duration of epilepsy;<BR/>(e) aetiology of epilepsy.</P>
<P>(3) Type of intervention and control.</P>
<P>(4) Duration of follow-up.</P>
<P>(5) Outcome data as described above.</P>
<P>We assessed clinical heterogeneity by comparing the distribution of important patient factors between trials (age, seizure type, duration of epilepsy, number of AEDs taken at time of randomization), and trial factors (randomization concealment, blinding, losses to follow-up).</P>
<P>We assessed statistical heterogeneity by using a chi square test where p &lt; 0.05 indicated significant heterogeneity. Provided no significant heterogeneity was present we used a fixed-effect model. Odds ratio or relative risk with 95% confidence intervals (CI) was used as appropriate for binary outcomes. We used weighted mean difference (WMD) with 95% CI for continuous data. All analyses included all patients in the treatment groups to which they were allocated.</P>
<P>Where the interventions were the same or similar, we synthesized results in a meta-analysis provided it seemed to be appropriate and there was no important clinical or statistical heterogeneity.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-08-07 20:52:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-08-07 20:52:48 +0100" MODIFIED_BY="[Empty name]">
<P>Among 25 studies that were identified as potentially relevant, 15 studies met the criteria for this review. The details of the other ten studies are given in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. The interventions used included thiamine supplementation in one study (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>), vitamin D in two studies (<LINK REF="STD-Christiansen-1973a" TYPE="STUDY">Christiansen 1973a</LINK>; <LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>) folic acid in twelve studies (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>; <LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Brown-1991" TYPE="STUDY">Brown 1991</LINK>; <LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>; <LINK REF="STD-Poppell-1991" TYPE="STUDY">Poppell 1991</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>) and vitamin E in one study (<LINK REF="STD-Ogunmekan-1989" TYPE="STUDY">Ogunmekan 1989</LINK>). Two studies were conducted in children less than 14 years of age (<LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>), one study in children and adolescents (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>), two studies included both children and adults (<LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Ogunmekan-1989" TYPE="STUDY">Ogunmekan 1989</LINK>), and the remaining ten studies recruited adults. Three were performed in adults with learning difficulty and epilepsy (<LINK REF="STD-Brown-1991" TYPE="STUDY">Brown 1991</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Poppell-1991" TYPE="STUDY">Poppell 1991</LINK>) and one (<LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>) included participants with both learning difficulty and physical disabilities. In all the studies vitamins were given as add-on to AEDs.</P>
<P>In total, these studies enrolled 808 participants with epilepsy and the results of 706 participants were included in this review. The number of patients enrolled (and analyzed) for intervention with thiamine, vitamin D, folic acid and vitamin E were 75 (72), 274 (251), 435 (359) and 24 (24) respectively. The gender distribution of the enrolled participants was not available for five studies. (<LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>). One hundred and two participants withdrew from these studies for various reasons such as recurrent illness, change of residence, withdrawal of consent, increase in seizure frequency, protocol violations, difficulty in obtaining blood sample and behavioral problems.</P>
<P>The outcomes assessed included the effects of thiamine on IQ scores; the effects of vitamin D on bone mineral content, serum calcium, serum alkaline phosphatase and general well-being; the effects of folic acid on various aspects of dental hygiene, neuropsychological tests, hematological parameters, seizure freqency, serum levels of AEDs, and nerve conduction studies. Further details of these studies are given in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. We did not find any randomized study of other vitamins such as pyridoxine, retinol, riboflavine, niacin, pantothenic acid, cyanocobalamin, ascorbic acid, ergosterol, menadione and vitamin U, which met our inclusion criteria.<BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The studies were small, of poor quality, prone to bias and results therefore unreliable. Among the included studies, four were cross-over (<LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Ogunmekan-1989" TYPE="STUDY">Ogunmekan 1989</LINK>) and the remainder were parallel studies. </P>
<P>The randomization sequence was generated using "random sampling numbers" in two studies (<LINK REF="STD-Christiansen-1973a" TYPE="STUDY">Christiansen 1973a</LINK>; <LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>) and by "pill count" method (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>). The method of random list generation was not described in six studies (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>; <LINK REF="STD-Brown-1991" TYPE="STUDY">Brown 1991</LINK>; <LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Ogunmekan-1989" TYPE="STUDY">Ogunmekan 1989</LINK>; <LINK REF="STD-Poppell-1991" TYPE="STUDY">Poppell 1991</LINK>). None of the included studies described how randomization was concealed, and may thus be prone to bias. </P>
<P>Blinding method was not mentioned in seven studies (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Brown-1991" TYPE="STUDY">Brown 1991</LINK>; <LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>). Eleven studies were double blinded. Among them four studies (<LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>; <LINK REF="STD-Ogunmekan-1989" TYPE="STUDY">Ogunmekan 1989</LINK>) were blinded by using similar packaging for both the placebo and the specified vitamin. In the other seven studies blinding methods were not described.</P>
<P>In some studies, the analysis did not include all enrolled participants. Among the 60 participants enrolled, only 27 were analyzed in one study (<LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>), since the remaining 33 had serum folate greater than 3 ng/ml. Many of the included studies were undertaken 20 to 30 years ago (<LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Christiansen-1973a" TYPE="STUDY">Christiansen 1973a</LINK>; <LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>), and since then the rigor of undertaking and reporting RCTs has improved.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>
<I>Effects of treatment with thiamine</I>
</B>
<I>
<BR/>
</I>No data available regarding seizure freedom, seizure frequency and quality of life. </P>
<P>
<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>, studied the effects of thiamine supplementation on neuropsychological tests (verbal and performance IQ) in 72 participants. The study found that thiamine improves neuropsychological functions related to psychomotor speed, visuospatial abilities, selective attention and verbal abstracting ability. The study found no significant effect on information, comprehension, picture completion or object assembly tests. The study which also had a folic acid arm did not find any significant benefit with folic acid while combined administration of folic acid and thiamine were associated with lower scores in information and digit span under verbal IQ score, than either vitamin given alone.</P>
<P>
<B>
<I>Effects of treatment with vitamin D</I>
</B>
<I>
<BR/>
</I>No data available regarding seizure freedom, seizure frequency. </P>
<P>Two studies (<LINK REF="STD-Christiansen-1973a" TYPE="STUDY">Christiansen 1973a</LINK>; <LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>) investigated the effect of vitamin D on well-being measured by questionnaire. Nineteen out of 116 adults treated with vitamin D subjectively (<LINK REF="STD-Christiansen-1973a" TYPE="STUDY">Christiansen 1973a</LINK>) felt better, compared to 25 out of 110 adults in the placebo group (Peto OR 0.67; 95% CI 0.34 to 1.29), whilst 5 out of 14 children treated with vitamin D (<LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>) felt better compared to 0 out of 11 children in the placebo group (Peto OR (95% CI) 13.32 (0.65, 272.84)).</P>
<P>Vitamin D on serum calcium and alkaline phosphatase: Two studies (<LINK REF="STD-Christiansen-1973a" TYPE="STUDY">Christiansen 1973a</LINK>; <LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK>) found no significant change in serum calcium or alkaline phosphatase in the vitamin D treated groups compared to the placebo groups.</P>
<P>Two studies (<LINK REF="STD-Christiansen-1973a" TYPE="STUDY">Christiansen 1973a</LINK>; <LINK REF="STD-Christiansen-1975" TYPE="STUDY">Christiansen 1975</LINK> ) recruiting a total of 251 participants investigated the effect of vitamin D on the bone. An actual value for bone mineral content (BMC) was available in only one study, which enrolled 226 adults (116 randomized to treatment group and 110 controls). The study found significantly higher BMC among patients with epilepsy who were receiving AEDs with Vitamin D supplementation compared to those who were not given vitamin D supplementation. (OR 3.6; 95% CI 2.48 to 4.72; p &lt; 0.00001). The second study enrolling 25 children also found a beneficial effect, but this study does not give the actual values of alteration in BMC. </P>
<P>
<B>
<I>Effects of treatment with vitamin E</I>
</B>
<I>
<BR/>
</I>One study enrolling 24 subjects (<LINK REF="STD-Ogunmekan-1989" TYPE="STUDY">Ogunmekan 1989</LINK>) found significant seizure reduction (60% or greater decrease in frequency of seizure) in the treatment group (p = 0.00005; Peto OR 26.73; 95% CI 5.46 to 130.92).</P>
<P>No data available regarding quality of life and reduction of side effects.</P>
<P>
<B>
<I>Effects of treatment with folic acid</I>
</B>
<I>
<BR/>
</I>Folic acid and seizure frequency: Nine studies enrolling 331 participants (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>; <LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>), investigated the effect on seizures. Sufficient data on seizure frequency were not available from seven studies (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>; <LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>). Two studies (75 participants) (<LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>) reported 50% reduction in seizure frequency, and no significant effect was found (OR 0.96 95% CI 0.32, 2.9).</P>
<P>No data available regarding quality of life. </P>
<P>
<B>
<I>Folic acid and hematological parameters<BR/>
</I>
</B>Two studies (<LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>) enrolling 62 participants investigated the effects of folic acid on hematological parameters. Neither study found a significant effect on hemoglobin content, hematocrit, mean corpuscular volume or mean corpuscular hemoglobin concentration.</P>
<P>
<B>
<I>Folic acid on AEDs<BR/>
</I>
</B>Seven studies enrolling 235 participants (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Brown-1991" TYPE="STUDY">Brown 1991</LINK>; <LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>; <LINK REF="STD-Poppell-1991" TYPE="STUDY">Poppell 1991</LINK>) investigated the effects of folic acid on phenytoin levels, while three enrolling 137 participants investigated the effects on phenobarbitone levels (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>). Three studies found no significant change in phenytoin concentration (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Gibberd-1981" TYPE="STUDY">Gibberd 1981</LINK>; <LINK REF="STD-Poppell-1991" TYPE="STUDY">Poppell 1991</LINK>), two found slight decrease in phenytoin levels (<LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>) while in one study (<LINK REF="STD-Brown-1991" TYPE="STUDY">Brown 1991</LINK>) firm conclusions could not be drawn due to changes in phenytoin dosages. In one study (<LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>) the participants using topical folic acid had higher mean phenytoin concentration all through the study period (including baseline), but the changes were not statistically significant. Two studies (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>) found no effect of folic acid on phenobarbitone levels, while the other (<LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>) found significant decrease in levels of phenobarbitone compared to controls. </P>
<P>
<B>
<I>Folic acid on peripheral nerve<BR/>
</I>
</B>One study (<LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>) investigated the effects of folic acid on 12 participants with neuropathy. After therapy the authors found no significant improvement in the mean motor conduction velocities. The authors also found that that there was no relation between serum folate levels and severity of the neuropathy. The authors have provided only the mean values of motor nerve conduction. Since the authors have not given the standard deviation or the actual values for the observations, we are unable to analyze the data further. </P>
<P>
<B>
<I>Dental hygiene<BR/>
</I>
</B>Five studies (analyzing 110 participants) (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>; <LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Brown-1991" TYPE="STUDY">Brown 1991</LINK>; <LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>; <LINK REF="STD-Poppell-1991" TYPE="STUDY">Poppell 1991</LINK>) investigated the effect of folic acid on dental health. The various poorly and variably defined outcomes in these studies are gingival hyperplasia index, the pocket depth, the plaque index, the gingival index, the mid-facial and interproximal overgrowth indices. Gingival hyperplasia is measured by the use of projected Kodachrome slides and study casts. The hyperplasia index utilised ranges from 0 to 4 and measures the degree of extent of gingival hyperplasia. A score of 0 means no clinical signs of hyperplasia, 1 = minimal hyperplasia, 2 = moderate, 3 = marked, and 4 = severe hyperplasia. Pocket depth in the gingiva was assessed by probing. The Plaque Index measures thickness of plaque in the dental surfaces, using a disclosing solution. It is scored in the ascending order starting from absence of plaque to full plaque. Gingival index measures the inflammation of gingiva as measured by colour, oedema, bleeding, and ulceration. It is also graded in the ascending order starting with normal gingival to highly inflamed gingiva. The percentage of changes in gingival overgrowth was assessed by indices such as "mid-facial overgrowth" changes, interproximal overgrowth changes. The impressions from the teeth were used to produce a die (positive replica of tooth). Die analysis with the help of an optical comparator and micro computer yielded the mid-facial overgrowth changes and interproximal overgrowth changes. These changes were compared between the treatment and the control group. Poorly defined outcomes such as dental hygiene, overall gingival condition and gingival health were used in some studies. Folic acid was administered orally in five studies and by topical application in one. One study investigated oral and topical administration (<LINK REF="STD-Drew-1987" TYPE="STUDY">Drew 1987</LINK>). The duration of study varied from 16 weeks to 180 days. None of the studies revealed any significant improvement in dental health, assessed by any of the parameters. </P>
<P>
<B>
<I>Folic acid and intelligence and behavior<BR/>
</I>
</B>Seven studies enrolling 302 participants (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>) investigated the effects of folic acid on intelligence, behavior or personality. The studies reported no significant changes in intelligence (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>), behavior (<LINK REF="STD-Bowe-1971" TYPE="STUDY">Bowe 1971</LINK>; <LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>), "mental state" (<LINK REF="STD-Horwitz-1968" TYPE="STUDY">Horwitz 1968</LINK>; <LINK REF="STD-Jensen-1970" TYPE="STUDY">Jensen 1970</LINK>) or personality as assessed by the Minnesota Multiphasic Personality Inventory (MMPI) (<LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>) or personality inventory scale (<LINK REF="STD-Grant-1970" TYPE="STUDY">Grant 1970</LINK>). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The studies included in this review investigate the effects of thiamine, folic acid, vitamin D and vitamin E given as add-on to AEDs in people with epilepsy. The outcomes studied included seizure frequency, effects on intelligence, memory, personality, behavior, effects on dental health, peripheral nerve, AED levels, effects on serum calcium, alkaline phosphatase and BMC. The number of participants studied for each outcome is low. The drop-outs from these studies increase the bias. The inclusion criteria have been diverse - three of the 15 studies were among mentally or developmentally handicapped participants. The outcomes have not been reported in detail. Some studies report mean seizure frequency instead of giving the 50% reduction in seizure frequency. One study has included individuals with short-term phenytoin therapy (<LINK REF="STD-Backman-1989" TYPE="STUDY">Backman 1989</LINK>). In general the influence of dietary intake of vitamin has not been investigated in these studies. The wash-out period in the cross-over trials is not mentioned. Two studies used a combination of vitamins, namely folate and thiamine (<LINK REF="STD-Botez-1993" TYPE="STUDY">Botez 1993</LINK>); folate and cyanocobalamin (<LINK REF="STD-Mattson-1973" TYPE="STUDY">Mattson 1973</LINK>). The results are graphically represented in some studies without giving the actual values (<LINK REF="STD-Poppell-1991" TYPE="STUDY">Poppell 1991</LINK>; <LINK REF="STD-Ralston-1970" TYPE="STUDY">Ralston 1970</LINK>). The deficiencies in randomization and blinding have already been highlighted in the section 'Methodological qualities of included studies'. </P>
<P>One study found that vitamin D administration improved bone mineral content among persons with epilepsy who were taking phenytoin, primidone and phenobarbitone. The authors have not attempted to correlate their findings with the type of antiepileptic drug. Moreover this study is nearly 30 years old and the methods of assessment of BMC may not have been as sophisticated at that time. Also prescription trends/practice of AEDs have changed over the years with decreasing use of phenytoin, primidone and phenobarbitone. Hence the relevance of this study and applicability to the present day therapeutic regime remains uncertain. Clinical events such as fractures may be more meaningful things to measure in the future. </P>
<P>Thiamine was found to improve neuropsychological functions related to psychomotor speed, visuospatial abilities, selective attention and verbal abstracting ability. However, the number of participants studied (per intervention) is low. The study also found that combined administration of folic acid and thiamine caused lower scores in information and digit span under verbal IQ score, than either vitamin given alone. Hence the results need to be interpreted with caution. </P>
<P>The use of folic acid did not result in any significant effect for any of the outcomes investigated (seizure frequency, gingival health, hematological parameters, intelligence, behavior or nerve conduction or serum levels of AEDs. </P>
<P>The only study on vitamin E included in this review reported a beneficial effect on seizure frequency. Since the number of patients studied is low and the confidence intervals are wide, the results need to be interpreted with caution. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>We found no reliable evidence to indicate that vitamins improve seizure control, reduce side effects of AEDs, improve cognitive function or improve quality of life. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further well designed, double blind randomized controlled trials with an adequate sample size and masked assessment of outcome are needed to evaluate the utility of vitamin D on bone mineral content especially in the context of the present day AEDs. Similarly, a larger study of vitamin E on seizure frequency and effect of thiamine on neuropsychological functions is also needed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Both review authors jointly developed the protocol, search strategy, data extraction and writing of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Backman-1989" NAME="Backman 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Backman N, Holm AK, Blomquist HK, Hiejbel J, Safstrom G</AU>
<TI>Folate treatment of diphenylhydantoin-induced gingival hyperplasia</TI>
<SO>Scandinavian Journal of Dental Research</SO>
<YR>1989</YR>
<VL>97</VL>
<NO>3</NO>
<PG>222-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Botez-1993" NAME="Botez 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Botez MI, Botez T, Ross-Chouinard A, Lalonde R</AU>
<TI>Thiamine and folate treatment of chronic epileptic patients: a controlled study with the Wechsler IQ scale</TI>
<SO>Epilepsy Research</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowe-1971" NAME="Bowe 1971" YEAR="1971">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bowe JC, Cornish EJ, Dawson M</AU>
<TI>Evaluation of folic acid supplements in children taking phenytoin</TI>
<SO>Developmental Medicine and Child Neurology</SO>
<YR>1971</YR>
<VL>13</VL>
<PG>343-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1991" NAME="Brown 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown RS, Di Stanislao PT, Beaver WT, Bottomley WK</AU>
<TI>The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia</TI>
<SO>Oral Surgery, Oral Medicine and Oral Pathology</SO>
<YR>1991</YR>
<VL>71</VL>
<PG>565-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1973a" NAME="Christiansen 1973a" YEAR="1973">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen C, Rodbro P, Lund M</AU>
<TI>Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>4</VL>
<NO>5894</NO>
<PG>695-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1975" NAME="Christiansen 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen C, Rodbro P, Nielsen CT</AU>
<TI>Iatrogenic osteomalacia in epileptic children</TI>
<SO>Acta Paediatrica</SO>
<YR>1975</YR>
<VL>64</VL>
<NO>2</NO>
<PG>219-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drew-1987" NAME="Drew 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Drew HJ, Vogel RI, Molofsky W, Baker H, Frank O</AU>
<TI>Effect of folate on phenytoin hyperplasia</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>6</NO>
<PG>350-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibberd-1981" NAME="Gibberd 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gibberd FB, Nicholls A, Wright MG</AU>
<TI>The influence of folic acid on the frequency of epileptic attacks</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1981</YR>
<VL>19</VL>
<NO>1</NO>
<PG>57-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grant-1970" NAME="Grant 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grant RH, Stores OP</AU>
<TI>Folic acid in folate-deficient patients with epilepsy</TI>
<SO>British Medical Journal</SO>
<YR>1970</YR>
<VL>4</VL>
<NO>736</NO>
<PG>644-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horwitz-1968" NAME="Horwitz 1968" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Horwitz SJ, Klipstein FA, Lovelace RE</AU>
<TI>Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>1</VL>
<NO>7542</NO>
<PG>563-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1970" NAME="Jensen 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jensen ON, Olesen OV</AU>
<TI>Subnormal serum folate due to anticonvulsive therapy. A double blind study of the effect of folic acid treatments in patients with drug-induced subnormal serum folates</TI>
<SO>Archives of Neurology</SO>
<YR>1970</YR>
<VL>22</VL>
<NO>2</NO>
<PG>181-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattson-1973" NAME="Mattson 1973" YEAR="1973">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mattson RH, Gallagher BB, Reynolds EH, Glass D</AU>
<TI>Folate therapy in epilepsy. A controlled study</TI>
<SO>Archives of Neurology</SO>
<YR>1973</YR>
<VL>29</VL>
<NO>2</NO>
<PG>78-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogunmekan-1989" NAME="Ogunmekan 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ogunmekan AO, Hwang PA</AU>
<TI>A Randomized, double-blind, placebo-controlled, clinical trial of D-alpha-tocopheryl acetate (vitamin E), as add-on therapy, for epilepsy in children</TI>
<SO>Epilepsia</SO>
<YR>1989</YR>
<VL>30</VL>
<NO>1</NO>
<PG>84-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poppell-1991" NAME="Poppell 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poppell TD, Keeling SD, Collins JF, Hassell TM</AU>
<TI>Effect of folic acid on recurrence of phenytoin-induced gingival overgrowth following gingivectomy</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>2</NO>
<PG>134-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ralston-1970" NAME="Ralston 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ralston AJ, Snaith RP, Hinley JB</AU>
<TI>Effect of folic acid on fit-frequency and behaviour in epileptics on anticonvulsants</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>1</VL>
<NO>7652</NO>
<PG>867-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1973b" NAME="Christiansen 1973b" YEAR="1973">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen C, Rodbro P, Lund M</AU>
<TI>Effect of vitamin D on bone mineral mass in normal subjects and in epileptic patients on anticonvulsants: a controlled therapeutic trial</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>2</VL>
<NO>5860</NO>
<PG>208-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1974" NAME="Christiansen 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Claus Christiansen, Paul Rodbro, Ole Sjo</AU>
<TI>"Anticonvulsant Action" of vitamin D in epileptic patients? A controlled pilot study</TI>
<SO>British Medical Journal</SO>
<YR>1974</YR>
<VL>2</VL>
<NO>913</NO>
<PG>258-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jekovec_x002d_Vrhovse-2000" NAME="Jekovec-Vrhovse 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jekovec-Vrhovse M, Kocijancic A, Prezelj J</AU>
<TI>Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full time care</TI>
<SO>Developmental Medicine and Child Neurology</SO>
<YR>2000</YR>
<VL>42</VL>
<PG>403-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiao-1997" NAME="Jiao 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jiao FY, Gao DY, Takuma Y, Wu S, Liu ZY, Zhang XK et al</AU>
<TI>Randomized, controlled trial of high dose intravenous pyridoxine in the treatment of recurrent seizures in children</TI>
<SO>Pediatric Neurology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKiernan-1981" NAME="McKiernan 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McKiernan J, Mellor DH, Court S</AU>
<TI>A controlled trial of pyridoxine supplementation in children with febrile convulsions</TI>
<SO>Clinical Pediatrics</SO>
<YR>1981</YR>
<VL>20</VL>
<NO>3</NO>
<PG>208-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1972" NAME="Moore 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moore JR, Ball EW</AU>
<TI>Folic acid replacement in folate-deficient children on anticonvulsants</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1972</YR>
<VL>47</VL>
<NO>252</NO>
<PG>309-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norris--1971" NAME="Norris  1971" YEAR="1971">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Norris JW, Pratt RF</AU>
<TI>A controlled study of folic acid in epilepsy</TI>
<SO>Neurology</SO>
<YR>1971</YR>
<VL>21</VL>
<NO>6</NO>
<PG>659-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raju-1994" NAME="Raju 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raju GB, Behari M, Prasad K, Ahuja GK</AU>
<TI>Randomized, double-blind, placebo-controlled, clinical trial of D-alpha-tocopherol (vitamin E) as add-on therapy in uncontrolled epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>2</NO>
<PG>368-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodbro-1975" NAME="Rodbro 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roodbro P, Christiansen C, Lund M</AU>
<TI>Subjective symptoms in epileptic patients on anticonvulsant drugs</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1975</YR>
<VL>52</VL>
<NO>2</NO>
<PG>87-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tjellesen-1985" NAME="Tjellesen 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tjellesen L, Gotfredsen, Christiansen C</AU>
<TI>Different actions of vitamin D2 and D3 on bone metabolism in patients treated with phenobarbitone/phenytoin</TI>
<SO>Calcified Tissue International</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>3</NO>
<PG>218-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Adab-2004" NAME="Adab 2004" TYPE="COCHRANE_REVIEW">
<AU>Adab N, Tudur Smith C, Vinten J, Williamson P, Winterbottom J</AU>
<TI>Common antiepileptic drugs in pregnancy in women with epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bazil-2003" NAME="Bazil 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bazil CW, Pedley TA</AU>
<TI>Clinical pharmacology of antiepileptic drugs</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>1</NO>
<PG>38-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christiansen-1974" NAME="Christiansen 1974" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen C, Rodbro P, Sjo O</AU>
<TI>"Anticonvulsant action" of vitamin D in epileptic patients? A controlled pilot study</TI>
<SO>British Medical Journal</SO>
<YR>1974</YR>
<VL>2</VL>
<NO>913</NO>
<PG>258-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Commission-1989" NAME="Commission 1989" TYPE="JOURNAL_ARTICLE">
<AU>Commission on Classification and Terminology of the International League Against Epilepsy</AU>
<TI>Proposal for revised classification of epilepsies and epileptic syndromes</TI>
<SO>Epilepsia</SO>
<YR>1989</YR>
<VL>30</VL>
<PG>389-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dorland-1994" NAME="Dorland 1994" TYPE="BOOK">
<SO>Dorland's Illustrated Medical Dictionary</SO>
<YR>1994</YR>
<EN>28th</EN>
<PB>Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Sayed-1998" NAME="El Sayed 1998" NOTES="&lt;p&gt;El-Sayed 1998&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>El-Sayed YY</AU>
<TI>Obstetric and gynaecologic care of women with epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1998</YR>
<VL>39</VL>
<NO>suppl 8</NO>
<PG>S17-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2001" NAME="Gupta 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gupta VK, Mishra D, Mathur I, Singh KK</AU>
<TI>Pyridoxine-dependent seizures: a case report and critical review of the literature</TI>
<SO>Journal of Paediatric Child Health</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>6</NO>
<PG>592-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-1993" NAME="Hauser 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hauser WA, Annegers JF, Kurland LT</AU>
<TI>Incidence of epilepsy and unprovoked seizure in Rochester, Minnesota:1935-1984</TI>
<SO>Epilepsia</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>3</NO>
<PG>453-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holland-2001" NAME="Holland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Holland KD</AU>
<TI>Efficacy, pharmacology and adverse effects of antiepileptic drugs</TI>
<SO>Neurologic Clinics</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>2</NO>
<PG>313-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horwitz-1968" NAME="Horwitz 1968" TYPE="JOURNAL_ARTICLE">
<AU>Horwitz SJ, Klipstein FA, Lovelace RE</AU>
<TI>Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>1</VL>
<NO>7542</NO>
<PG>563-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jiao-1997" NAME="Jiao 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jiao FY, Gao DY, Takuma Y, Wu S, Liu ZY, Zhang XK et al</AU>
<TI>Randomized, controlled trial of high-dose intravenous pyridoxine in the treatment of recurrent seizures in children</TI>
<SO>Pediatric Neurology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindhout-1986" NAME="Lindhout 1986" NOTES="&lt;p&gt;Lindhout 1986&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lindhout D, Schmidt D</AU>
<TI>In-utero exposure to valproate and neural tube defects</TI>
<SO>The Lancet</SO>
<YR>1986</YR>
<VL>1</VL>
<NO>8494</NO>
<PG>1392-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lumley-2001" NAME="Lumley 2001" TYPE="COCHRANE_REVIEW">
<AU>Lumley J, Watson L, Watson M, Bower C</AU>
<TI>Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marriott-1997" NAME="Marriott 1997" TYPE="JOURNAL_ARTICLE">
<AU>Marriott BM</AU>
<TI>Vitamin D Supplementation: a word of caution</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>127</VL>
<NO>3</NO>
<PG>231-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raju-1994" NAME="Raju 1994" TYPE="JOURNAL_ARTICLE">
<AU>Raju GB, Behari M, Prasad K, Ahuja GK</AU>
<TI>Randomized, double-blind, placebo-controlled, clinical trial of D-alpha-tocopherol (vitamin E) as add-on therapy in uncontrolled epilepsy</TI>
<SO>Epilepsia</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>2</NO>
<PG>368-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rantala-1997" NAME="Rantala 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rantala H, Tarkka R, Uhari M</AU>
<TI>A meta-analytic review of the preventive treatment of recurrences of febrile seizures</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>131</VL>
<NO>6</NO>
<PG>922-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosa-1991" NAME="Rosa 1991" NOTES="&lt;p&gt;Rosa 1991&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rosa FW</AU>
<TI>Spina bifida in infants of women tested with carbamazepine during pregnancy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<NO>10</NO>
<PG>674-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sander-1996" NAME="Sander 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sander JW, Shorvon SD</AU>
<TI>Epidemiology of the epilepsies</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1996</YR>
<VL>61</VL>
<NO>5</NO>
<PG>433-43</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Backman-1989">
<CHAR_METHODS>
<P>Randomized controlled parallel study. Children with phenytoin treated convulsive disorders (majority had idiopathic generalized epilepsies or benign childhood epilepsy with centro temporal spikes) took part in study.<BR/>Study period = 1 year. Randomization method not mentioned. <BR/>Blinding - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center Swedish study of 44 children. (Number analyzed = 31). 23 receiving phenytoin for more than 1 year were randomized to treatment group (n = 10 - 5 boys and 5 girls) and control group (n = 13 - 6 boys and 7 girls).<BR/>The mean age 9.3 years in the treatment group and 10.23) in the control group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment group received folic acid 5 mg once daily. Control group did not receive any additional medication. AEDs were continued in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Serum phenytoin levels, plasma and red cell levels of folate, gingival hyperplasia, gingival bleeding, dental plaque were measured.<BR/>Medical and dental assessment was done at the start of study and 6 and 12 months later.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>13 were "dropped" from the study, since they did not have gingival hyperplasia.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Botez-1993">
<CHAR_METHODS>
<P>Double blind, randomized controlled parallel group study. <BR/>4 arms - Placebo, Folate, Thiamine, Folate + Thiamine.<BR/>Treatment period = 6 months. Follow-up after 6 months.<BR/>Inclusion criteria:<BR/>Adult out-patient with well controlled epilepsy receiving AEDs for at least 4 years prior to study with controlled pharmacological levels of AEDs.<BR/>Exclusion criteria:<BR/>Epilepsy due to tumors, degenerative, metabolic, demyelinating disease or acute infection. Alcohol, narcotics,<BR/>co-medications interfering with folate and Vitamin B12. Severe medical diseases. Psychotic and depressed patients IQ &lt; 75,<BR/>megaloblastic anemia due to folate deficiency. Pregnancy. Institutionalized patients. Deficient dietary vitamin intake.<BR/>Randomization procedure is by "Pill Count Method". Method of blinding - not mentioned.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center Canadian study of 72 adults.<BR/>M:F = 34:38.<BR/>Number of participants in groups 1, 2, 3, 4 are 22, 18, 16 and 16 respectively.<BR/>The mean age +/-SD of participants in the 4 groups were 43.45+/-11.71, 38.04+/-19.2, 40.75+/-16.7, 45.80+/-14.8 respectively.<BR/>The duration of education in groups 1, 2, 3, 4 are 8.66+/-3.19, 11.1+/-4.9, 8.67+/-2.9, 8.19+/-3.81 respectively.<BR/>The duration of epilepsy in group 1, 2, 3, 4 were 21.45+/-12.6, 18.44+/-11.45, 20.80+/-11.10, 20.62+/-13.2 respectively.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group 1 - 2 placebo tablets.<BR/>Group 2 - 1 folic acid tablet (5 mg) + 1 placebo<BR/>Group 3 - 1 placebo + 1 thiamine tablet (50 mg).<BR/>Group 4 - 1 folate + 1 thiamine tablet<BR/>along with their AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neuropsychiatric tests, verbal IQ, performance IQ and global score were measured. The verbal IQ subsets include information, comprehension, digit span, arithmetic, similarities were measured. <BR/>Performance IQ score includes subsets like picture arrangement, picture completion, block design, object assembly, digit symbol were measured. Assessment done at base line and after 6 months of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bowe-1971">
<CHAR_METHODS>
<P>Double blind cross-over study.<BR/>4 phases: I - Pretreatment<BR/>phase (3 months) <BR/>II - (3 months) Group I received folic acid and Group 2 received placebo. <BR/>III - cross-over folic acid or placebo (3 months).<BR/>IV- Post treatment. <BR/>Method of blinding - not mentioned.<BR/>Randomization - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center UK study.<BR/>Total Number = 50. Group I = 20 (16 men and 4 women) Group II = 18 (16 men and 2 women), <BR/>Control = 10. Drop outs = 12.<BR/>Mean age for the entire group = 13 +/- 0.5. <BR/>For groups I and II the duration of epilepsy was 9 +/-1 years and the duration of phenytoin therapy was 5.5 +/- 0.5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Folic acid tablets of 5 mg 3 times a day or placebo tablets given 3 times a day along with AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hematological data - Hb, PCV, MCHC.<BR/>Number of seizures, <BR/>Behavioral observation<BR/>by house parents and teachers.<BR/>Gum hyperplasia, oral hygiene and occlusion were recorded.<BR/>Observations were made at the end of each phase.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data taken just before the cross-over. 12 participants were excluded - difficulty in obtaining blood samples, behavioral problems, or departure from the school. The 10 participants in the control group probably did not have epilepsy for the last 2 years as there was no administration of hydantoin, barbitone or primidone for 2 years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brown-1991">
<CHAR_METHODS>
<P>Double blind, randomized, placebo controlled, parallel study. 2 arms - folic acid and placebo.<BR/>Treatment period = 16 weeks. Review at 0, 4, 8, 12 and 16 week<BR/>Randomization procedure not clear. Blinding method not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center US study (VA). <BR/>21 severely retarded epileptic adult residents<BR/>with epilepsy were studied. Number in treatment group = 10 (4 men and 6 women) and placebo group = 11 (7 men and 3 women).<BR/>Mean age in treatment group = 26.02 and in control group = 26.32 years. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The treatment group received one 3 mg folic acid capsule daily, and the placebo group received daily lactose capsules in addition to AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Gingival hyperplasia index score, gingival health index, plaque index, serum folate and phenytoin levels were measured.<BR/>Assessment was done at the start and at 4, 8, 12 and at 16 weeks of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Number enrolled = 21. Number analyzed = 20. 1 participant was excluded (in the placebo group) for protocol violation. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Christiansen-1973a">
<CHAR_METHODS>
<P>Randomized controlled parallel group trial. 2 arms - vitamin D + calcium lactate, placebo + calcium lactate<BR/>Period of study = 3 months.<BR/>Exclusion criteria - digestive or renal disorder. None were disabled.<BR/>Randomization - through random sampling numbers. Blinding method - not clear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center study from Denmark.<BR/>Total number of participants = 249. 226 took part in study (116 randomized to treatment group and 110 to placebo). Group A comprised 151 participants treated with phenytoin<BR/>(92 men with mean age of 44, 59 women with mean age of 39).<BR/>Group B: comprised 16 participants (12 treated with phenobarbitone, and 4 with primidone). M:F = 7:9. Mean age was 43 for men and 32 for women. <BR/>Group C: 59 (47 - phenytoin + phenobarbitone, 12 - phenytoin+ primidone). M:F = 34:25. Mean age of males was 39 and mean age of females = 37.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment group received vitamin D2 2000 IU/day + calcium lactate (390 mg of Ca/day) - by mouth.<BR/>Placebo group received placebo + calcium lactate (390 mg/Ca/day) by mouth.<BR/>Vit D and placebo tablets contained CaHPO4 - a further daily supply of 125 mg calcium.<BR/>AEDs were taken in their usual dosage.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Bone mineral content, serum calcium, serum alkaline phosphatase and feeling of well-being were measured before and at the end of 3 months of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>23 persons declined the invitation to join the investigation. Control groups - did not have epilepsy and served as reference for bone mineral content, serum calcium, serum alkaline phosphatase. In addition to the treatment provided, the average daily vitamin D intake from food was about 200 IU.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Christiansen-1975">
<CHAR_METHODS>
<P>Randomized controlled parallel group trial. 2 arms - vitamin D and placebo. Duration of trial = 3 months.<BR/>Exclusion criteria - digestive or renal disorder. <BR/>Randomization through random sampling numbers. <BR/>Blinding - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center study from Denmark.<BR/>25 children, aged between 7 - 14 years, treated with phenytoin for at least 1 year. <BR/>14 were treated with Vitamin D and 11 with placebo.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Vit D2 2000 IU + calcium sandoz 500 mg by mouth daily for 3 months - for the treatment group<BR/>Calcium sandoz 500 mg per day + placebo - for the control group. AEDs were continued in the epileptic children.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BMC, serum calcium and serum alkaline phosphatase levels and phenytoin level was measured at the start and after 3 months of treatment. Feeling of well-being measured using a questionnaire.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Control Groups A (22 healthy children) and group B (101 healthy children) probably did not have epilepsy and served as control for BMC, serum calcium and alkaline phosphatase.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Drew-1987">
<CHAR_METHODS>
<P>Double blind, randomized, parallel study. 3 arms - folic acid tablet group, folic acid solution group and control group.<BR/>Period of study = 6 months<BR/>Inclusion criteria - active phenytoin therapy for a minimum of 3 years and displayed varying degrees of gingival hyperplasia.<BR/>Method of randomization not mentioned.<BR/>Blinding method - not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center US study. Total number of participants = 15.<BR/>M:F = 6:9.<BR/>Number analyzed = 13.<BR/>5 participants in the first 2 groups and 3 in the control group. <BR/>Age range 11 - 29 with mean of 17 years.<BR/>Many of the participants displayed varying degrees of physical and mental handicap.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Folic acid tablet (1 mg 2 tablets twice daily orally) + topical application of placebo solution; OR<BR/>Topical application of solution of folic acid + placebo tablet orally;<BR/>OR<BR/>placebo tablet orally + topical application of placebo solution.<BR/>The active and placebo tablets and solutions were identical. AEDs were continued in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Probing depths, plaque and gingival indices, serum folate and serum phenytoin are measured at 0, 90, 180 days of study.<BR/>Alginate impression and gingival hyperplasia are measured on 0,180 days of study.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 withdrew from control group due to illness unrelated to experiment.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gibberd-1981">
<CHAR_METHODS>
<P>Double blind randomized parallel trial. 2 arms - folic acid and placebo. Pre treatment phase lasted for 6 months (or up to 1 year if the patients had less than 5 seizures). Treatment phase lasted 6 months to 1 year. <BR/>Method of randomization - not mentioned.<BR/>Blinding method - identical looking folic acid and placebo tablet. Participants were included if they had "grand mal" seizures for at least 1 year and were receiving AEDs including phenytoin for at least 6 months and had therapeutic concentration of phenytoin on 3 occasions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center study from London UK. Total number of participants = 57. Treatment group = 29, control group = 28.<BR/>M:F = not mentioned<BR/>Age = not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Folic acid of 5 mg was administered 3 times a day to the treatment group and identical placebo to the control group. AEDs were continued in both groups.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Seizure frequency, serum folic acid, phenytoin and B12, hemoglobin and EEG <BR/>assessment was done at the start and end of pretreatment period and at the end of treatment period.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Number enrolled 61, number analyzed = 57. 4 participants withdrew from the study - 1 in trial group for failure to attend the program, 1 - in control group - unable to tolerate the placebo, 2 - in control group for illness unrelated to epilepsy. M:F ratio not given. Age range of patients not mentioned. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Grant-1970">
<CHAR_METHODS>
<P>Double blind, randomized, parallel study. 2 arms - folic acid and placebo.<BR/>Pre treatment baseline period = 26 weeks. Treatment period = minimum 26 weeks. <BR/>Participants with toxic levels of serum phenytoin were excluded. Patients whose serum folate levels &lt; 3.6ng/ml are included.<BR/>Randomization method - not mentioned.<BR/>Blinding - through identical looking tablets.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center UK study of 51 adult participants. Number analyzed = 48. 23 (12 men and 11 women) were randomized to folic acid group and 25 (12 men and 13 women) to placebo group.<BR/>Age range = 18 - 60 in folic acid and 16 - 65 in placebo.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Folic acid 5 mg 3 times a day.<BR/>Placebo 5 mg 3 times a day.<BR/>Anticonvulsant therapy remained static throughout the trial, unless change was essential on clinical grounds.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neuropsychological tests of intelligence, memory, personality, behavior, speech, mood, social relationship to patients, social relationship to staff, aggression, anger were studied.<BR/>Cognitive and memory tests were done before and after 26 weeks of treatment. Personality and behavior were assessed before the treatment and later done on a monthly basis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 in folic acid and 1 in placebo group were withdrawn. In 41 patients the "period of observation" was over 1 year. It is unclear whether this period refers to treatment phase or follow-up phase.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Horwitz-1968">
<CHAR_METHODS>
<P>Double blind controlled cross-over trial.<BR/>Trial period = 6 months.<BR/>Blinding method - not mentioned.<BR/>Randomization method - not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center US study. Among 52 patients (age range between 12 - 62) with chronic epilepsy who were receiving phenytoin for more than 5 years, 20 had absent reflexes. 12 of the 20 with absent reflexes entered the trial. 19 of the 20 participants were on phenytoin &gt; 10 years. <BR/>M:F = not given.<BR/>Age = not given.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The treatment group (n = 6) received 5 mg of folic acid for 3 months and the controls (n = 6) received placebo. Patients with epilepsy took their daily dosage of AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Nerve conduction, needle EMG, seizure frequency, mental status, serum levels of folate and B12. <BR/>Assessment was done at the pretreatment period and after 3 months of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>There is no mention of M:F ratio. There is no wash-out period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jensen-1970">
<CHAR_METHODS>
<P>Double blind, cross-over study.<BR/>Period of study = 5 months.<BR/>2 arms - folic acid, placebo.<BR/>Blinding method - not mentioned.<BR/>Randomization - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center study from Denmark.<BR/>Total number of patients = 24 adults (Average age = 34) with <BR/>mental subnormality and psychotic behavior. All had subnormal serum folate levels but had normal whole blood folate, serum B12, and peripheral blood picture.<BR/>M:F = not given.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1 group received placebo, the other group folic acid tablets (20 mg daily). AEDs were continued in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental status, seizure frequency.<BR/>Hematological parameters - Hb, PCV, MCV serum phenytoin and phenobarbital levels were recorded at the start of the study and at the time of cross-over.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only first phase data is taken. There is no mention about how many people were first administered with folic acid and how many with placebo.<BR/>Ratio of M:F is not given.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mattson-1973">
<CHAR_METHODS>
<P>Double blind controlled study<BR/>Observation period = 3 months. Experiment period = 6 months.<BR/>Patients were followed up at 2 weeks interval in the outdoor clinic and re-admitted at 3 and 6 months after the initiation of treatment for complete check up.<BR/>Blinding method - having identical folic acid and placebo pills.<BR/>Randomization method not mentioned.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center US study of 49 adult participants with epilepsy. Number analyzed = 41.<BR/>Participants whose serum folate concentration is &lt; = 7 ng/ml are alone included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment group received 5 mg of folic acid 3 times a day + 1 mg of intramuscular cyanocobalamin twice a month along with AEDs. Placebo group received identical pills and injections of placebo materials along with AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Seizure frequency, Psychometric tests of intelligence, memory, and MMPI. Serum and CSF levels of phenytoin, phenobarbital folate concentration in serum and CSF. Complete neurological assessment was done at the start and at 3 months and 6 months after initiation of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>8 participants were withdrawn. 2 in control group and 1 in treatment group were withdrawn for increase in seizure frequency<BR/>5 (2 in control and 3 in treatment) were unwilling to complete the study.<BR/>There is no clear indication as to the number of patients in the treatment group and in control group. <BR/>Since the second part consists of evaluating folate concentration in patients treated with leucovorin, which is out of scope of this study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ogunmekan-1989">
<CHAR_METHODS>
<P>Prospective, modified cross-over, randomized, double blind, placebo controlled trial.<BR/>It consists of 3 months of baseline period and 3 months of treatment period, followed by 3 months of vitamin E treatment, irrespective of the group. <BR/>Exclusion criteria - children &lt; 5 years, patients with malabsorption or gastrointestinal disturbances, patients receiving iron therapy, medication other than AEDs, patients undergoing change in AED dosage.<BR/>Blinding method - matching placebo and vitamin E tablet.<BR/>Randomization method not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center Canadian study of 24 children. 12 were randomized to the treatment group (M:F = 7:5, mean age = 10.8 years, mean age of seizure onset = 2.9 years, mean duration of epilepsy = 5.6 years) and 12 to control group (M:F= 6:6, mean age = 10.3 years, mean age of seizure onset = 2.6 years, mean duration of epilepsy = 5.5 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Vitamin E (294 mg) or matched placebo was administered as a single daily evening dose for 3 months, in addition to the patient's usual AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Seizure frequency, hematological and bio-chemical lab test were done. EEG was recorded at the start and end of the study.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 patient developed status epilepticus during the trial period after developing chicken pox. This patient was excluded from the final analysis of results.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Poppell-1991">
<CHAR_METHODS>
<P>Randomized controlled trial.<BR/>Study period = 6 months. 2 arms - folic acid and controls.<BR/>Inclusion Criteria: <BR/>moderate to advanced gingival overgrowth,<BR/>Mild to moderate mental retardation permitting surgical management and alginate impression.<BR/>Have not had gingivectomies previously, receiving phenytoin therapy for epilepsy for at least 2 years.<BR/>Blinding - unclear.<BR/>Randomization method - not mentioned.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center US study of 8 developmentally disabled institutionalized adult patients. 4 were in the treatment group (M:F = 1:3) and 4 in the control group (all men).<BR/>Age range in treatment group - 25 - 35.5 (mean = 30.6) and 23 - 35.5 (mean= 28.1).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Folic acid 5 mg daily was administered to the treatment group. Control group did not receive any additional medication.<BR/>All received a diet containing minimum daily requirements of vitamins and minerals.<BR/>AEDs were continued in all.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Frequency of seizure, red blood cell folate values, free phenytoin blood levels, plaque index, gingival index, mid-facial overgrowth changes and interproximal overgrowth changes were measured 4 times - baseline, immediately after gingivectomy and 3 and 6 months follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ralston-1970">
<CHAR_METHODS>
<P>Double blind control trial.<BR/>Duration of study = 3 months.<BR/>Follow-up - 2 months after trial.<BR/>2 arms - folate and placebo.<BR/>Participants whose serum folate &lt; 3 ng /ml were randomized to receive either folic acid or placebo. <BR/>Participants with epilepsy and receiving phenytoin or phenobarbitone or primidone, singly or in combination for at least 3 years were included. Method of blinding - not mentioned.<BR/>Randomization - not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Single center study from Yorkshire of<BR/>27 patients (22 men and 5 women) with epilepsy who had serum folate &lt; 3 ng/ml. <BR/>There were 14 participants in the treatment group (11 male and 3 female) and 13 in the placebo group (11 male and 2 female).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment group received folic acid 5 mg thrice daily for 3 months. The other group received placebo. Both groups took their AEDs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Seizure frequency, serum folate and serum Vitamin B12 and 4 aspects of behavior, namely, activity, noise disturbance, aggressiveness and destructiveness were measured. Fit frequency was measured daily and compared with number of fits for the 3 months immediately preceding the start of trial. Other outcomes were measured at the start and at the end of trial and 2 months later.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IU - International Units<BR/>EEG - Electro Encephalo Gram<BR/>PCV - Packed Cell Volume<BR/>MCHC - Mean Corpuscular Haemoglobin Concentration<BR/>MMPI - Minnesota Multiphasic Personality Inventory<BR/>MCV - Mean Corpuscular Volume<BR/>CSF - Cerebro Spinal Fluid<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Christiansen-1973b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes data not provided in detail for a meaningful analysis. Results are graphically represented and actual values not provided.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christiansen-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization appears to be inadequate and faulty since there are 9 subjects in one group and 14 in the other. The study period was too short (only 28 days) and Vitamin D was given to controls after 8 weeks without a wash-out period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jekovec_x002d_Vrhovse-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomization method appears to be inadequate. Those who consented for bone specific therapy were put in the intervention group and those who did not in the control group. The participants were bedridden and institutionalized with cerebral palsy and were tube-fed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jiao-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomization appears to be inadequate. Among 50 controls enrolled only 41 were analysed. Reasons for withdrawal not given. Most participants were suffering from "acute" symptomatic seizures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McKiernan-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Placebo used is ascorbic acid, which is another vitamin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moore-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Norris--1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Seizure data are not provided in detail. Hematological and neuropsychological effects are not given in detail to perform a meaningful analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raju-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-over study, data for the response during the first phase of the study are not available. The authors have been contacted, but the data were not available at the time of writing this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodbro-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study deals with subjective symptoms, rather than objective data. The study is from the same center as Christiansen 1973a. It is possible that there was an overlap of participants included in this study and in Christiansen 1973a, since the number of participants studied is the same in both studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tjellesen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison has been made between the effects of Vitamin D2 versus Vitamin D3 rather than with placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Backman-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Botez-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bowe-1971">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brown-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Christiansen-1973a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Christiansen-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Drew-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gibberd-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Grant-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Horwitz-1968">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mattson-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ogunmekan-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Poppell-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ralston-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Folic acid on cognition, behavior, memory and well-being</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parameter/ Scale</P>
</TH>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Remarks</P>
</TH>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Verbal IQ</P>
</TD>
<TD>
<P>No significant change between the folic acid group and control group</P>
</TD>
<TD>
<P>Verbal IQ - Information, comprehension, digit span, arithmetic and similarities</P>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Performance IQ</P>
</TD>
<TD>
<P>No significant change between the folic acid group and the control group</P>
</TD>
<TD>
<P>Performance IQ - Picture arrangement, picture completion, block design, object assembly, digit symbol</P>
</TD>
</TR>
<TR>
<TD>
<P>Bowe 1971</P>
</TD>
<TD>
<P>Behavior- Aberdeen London Child behaviour scales A &amp; B</P>
</TD>
<TD>
<P>Majority of them showed no change in behavior change during the trial</P>
</TD>
<TD>
<P>No significant change</P>
</TD>
</TR>
<TR>
<TD>
<P>Grant 1970</P>
</TD>
<TD>
<P>General Intelligence, Ravens progressive matrices 15 minute scores</P>
</TD>
<TD>
<P>No change between the folate and control group</P>
</TD>
<TD>
<P>General intelligence is through WAIS scale</P>
</TD>
</TR>
<TR>
<TD>
<P>Grant 1970</P>
</TD>
<TD>
<P>Behavior rating scale, Personality inventory scale</P>
</TD>
<TD>
<P>No significant change between the folic acid and placebo group</P>
</TD>
<TD>
<P>Behavior rating scale - 3 scales - neuroticism, extraversion and lie scale. Personality Inventory Scale - is by Eysenck - Withers scale</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1970</P>
</TD>
<TD>
<P>Mental State</P>
</TD>
<TD>
<P>No change in mental state of the patient</P>
</TD>
<TD>
<P>Scale of measurement is not mentioned</P>
</TD>
</TR>
<TR>
<TD>
<P>Ralston 1970</P>
</TD>
<TD>
<P>Behavior rating scale</P>
</TD>
<TD>
<P>No statistically significant change is noted between the treatment and control group</P>
</TD>
<TD>
<P>Validation/ Standardization of rating scale not mentioned</P>
</TD>
</TR>
<TR>
<TD>
<P>Mattson 1973</P>
</TD>
<TD>
<P>WAIS, Wechsler memory scale, MMPI</P>
</TD>
<TD>
<P>No change in cognitive performance between the folic acid and control group</P>
</TD>
<TD>
<P>No clear indication of the number of people in the treatment and control group</P>
</TD>
</TR>
<TR>
<TD>
<P>Horwitz 1968</P>
</TD>
<TD>
<P>Mental status</P>
</TD>
<TD>
<P>Unaffected by the folic acid therapy</P>
</TD>
<TD>
<P>Method of rating is not mentioned</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Effect of folic acid on hematological parameters</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH>
<P>STUDY</P>
</TH>
<TH>
<P>PARAMETER</P>
</TH>
<TH>
<P>RESULTS</P>
</TH>
</TR>
<TR>
<TD>
<P>Bowe 1971</P>
</TD>
<TD>
<P>MCHC</P>
</TD>
<TD>
<P>No significant change between the folate concentration and MCHC</P>
</TD>
</TR>
<TR>
<TD>
<P>Bowe 1971</P>
</TD>
<TD>
<P>Hemoglobin content</P>
</TD>
<TD>
<P>No significant change between the folate concentration and hemoglobin content</P>
</TD>
</TR>
<TR>
<TD>
<P>Bowe 1971</P>
</TD>
<TD>
<P>packed cell volume.</P>
</TD>
<TD>
<P>No significant change between the folate concentration and packed cell volume</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1970</P>
</TD>
<TD>
<P>Hemoglobin content</P>
</TD>
<TD>
<P>No significant change between the folate concentration and Hb content</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1970</P>
</TD>
<TD>
<P>Hematocrit (%)</P>
</TD>
<TD>
<P>No significant change between the folate concentration and hematocrit</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1970</P>
</TD>
<TD>
<P>Erythrocyte count</P>
</TD>
<TD>
<P>No significant change between the folate concentration and erythrocyte count</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1970</P>
</TD>
<TD>
<P>MCV</P>
</TD>
<TD>
<P>No significant change between the folate concentration and MCV</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Effect of folic acid on intelligence</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parameter</P>
</TH>
<TH>
<P>Control score</P>
</TH>
<TH>
<P>Folic acid score</P>
</TH>
<TH>
<P>P value</P>
</TH>
<TH>
<P>Remarks</P>
</TH>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Digit span</P>
</TD>
<TD>
<P>10.6</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Similarities</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>13.3</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Total verbal score</P>
</TD>
<TD>
<P>105.3</P>
</TD>
<TD>
<P>106.4</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>No significant improvement in verbal IQ score after folic acid supplementation</P>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Block design</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Digit symbol</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Total performance IQ score</P>
</TD>
<TD>
<P>102.4</P>
</TD>
<TD>
<P>103.3</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Total IQ score</P>
</TD>
<TD>
<P>105.4</P>
</TD>
<TD>
<P>106.4</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>No significant improvement in performance IQ or in total IQ score after folic acid supplementation</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Effect of folic acid on dental hygiene</TITLE>
<TABLE COLS="3" ROWS="3">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parameter</P>
</TH>
<TH>
<P>Results</P>
</TH>
</TR>
<TR>
<TD>
<P>Backman 1989</P>
</TD>
<TD>
<P>Dental hygiene</P>
</TD>
<TD>
<P>In the folate group, gingival hyperplasia remain unchanged in 45/55 sextants, 10/55 showed mild reduction and none showed any increase. In the control group 47/61 sextants remain unchanged, 8/61 decreased and 6/61 increased</P>
</TD>
</TR>
<TR>
<TD>
<P>Poppell 1991</P>
</TD>
<TD>
<P>Dental hygiene, gingival index, plaque index</P>
</TD>
<TD>
<P>No significant change between the folic acid treated group and control group.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>Effect of folic acid on AEDs</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>On phenytoin</P>
</TH>
<TH>
<P>On Phenobarbital</P>
</TH>
</TR>
<TR>
<TD>
<P>Gibberd 1981</P>
</TD>
<TD>
<P>No change in phenytoin concentration between the treatment and control group</P>
</TD>
<TD>
<P>Not studied</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1970</P>
</TD>
<TD>
<P>There is slight decrease in the serum levels of diphenylhydantoin</P>
</TD>
<TD>
<P>Completely unaffected by folic acid treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Poppell 1991</P>
</TD>
<TD>
<P>Changes in free phenytoin blood levels is insignificant</P>
</TD>
<TD>
<P>Not analyzed</P>
</TD>
</TR>
<TR>
<TD>
<P>Mattson 1973</P>
</TD>
<TD>
<P>There is slight decrease in folic acid treated group, but not significant</P>
</TD>
<TD>
<P>In the folic acid treated group, the levels of serum and CSF phenobarbitol decreased significantly compared to control group, where it increased.</P>
</TD>
</TR>
<TR>
<TD>
<P>Brown 1991</P>
</TD>
<TD>
<P>Changes in PHT levels were difficult to interpret, since PHT dosages were changed accordingly</P>
</TD>
<TD>
<P>Not analyzed</P>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>No statistical significant change between the groups after folic acid supplementation</P>
</TD>
<TD>
<P>No statistical significant change after folic acid supplementation</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>Effect of folic acid on seizures</TITLE>
<TABLE COLS="3" ROWS="9">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Remarks</P>
</TH>
</TR>
<TR>
<TD>
<P>Bowe 1971</P>
</TD>
<TD>
<P>No significant difference in the mean number of seizures were recorded in the entire experiment</P>
</TD>
<TD>
<P>Actual values for seizure frequency are not available, only mean number of seizures is given</P>
</TD>
</TR>
<TR>
<TD>
<P>Drew 1987</P>
</TD>
<TD>
<P>No reported increase in seizure frequency in any individual</P>
</TD>
<TD>
<P>Actual values for seizure frequency are not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Gibberd 1981</P>
</TD>
<TD>
<P>No statistically significant change in frequency in the treatment group</P>
</TD>
<TD>
<P>Self reported feeling of well-being was not found significant</P>
</TD>
</TR>
<TR>
<TD>
<P>Backman 1989</P>
</TD>
<TD>
<P>No significant change in the control of seizure during the year of the study between the groups</P>
</TD>
<TD>
<P>Actual values for seizure frequency are not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1970</P>
</TD>
<TD>
<P>No change that could be ascribed to the folic acid administration were observed in the fit frequency</P>
</TD>
<TD>
<P>Actual values for seizure frequency are not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Ralston 1970</P>
</TD>
<TD>
<P>6/14 had higher frequency in the treatment group. 5/13 had higher frequency in control group - statistically not significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mattson 1973</P>
</TD>
<TD>
<P>No significant or consistent alteration in seizure control between the treatment and control group</P>
</TD>
<TD>
<P>Actual values for seizure frequency are not available separately for the two groups.</P>
</TD>
</TR>
<TR>
<TD>
<P>Horwitz 1968</P>
</TD>
<TD>
<P>Seizure frequency is unaffected by folic acid therapy</P>
</TD>
<TD>
<P>Actual values for seizure frequency are not available</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" NO="7">
<TITLE>Effect of vitamin D on bone</TITLE>
<TABLE COLS="4" ROWS="9">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parameter</P>
</TH>
<TH>
<P>Observation</P>
</TH>
<TH>
<P>Remarks</P>
</TH>
</TR>
<TR>
<TD>
<P>Christiansen 1973a</P>
</TD>
<TD>
<P>Serum Calcium</P>
</TD>
<TD>
<P>No statistically significant change seen</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Christiansen 1973a</P>
</TD>
<TD>
<P>Serum Alkaline Phosphatase</P>
</TD>
<TD>
<P>No statistically significant change seen</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Christiansen 1973a</P>
</TD>
<TD>
<P>Well Being</P>
</TD>
<TD>
<P>19/116 on vitamin D felt better compared to 25/110 in control group</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Christiansen 1973a</P>
</TD>
<TD>
<P>Bone mineral content</P>
</TD>
<TD>
<P>Statistically significant rise of BMC noted in vitamin D treated epileptics</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Christiansen 1975</P>
</TD>
<TD>
<P>Serum Calcium</P>
</TD>
<TD>
<P>Serum calcium increased in both vitamin D and placebo groups. Calcium levels were not correlated to dose or duration of AED treatment.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Christiansen 1975</P>
</TD>
<TD>
<P>Serum Alkaline Phosphatase</P>
</TD>
<TD>
<P>No statistically significant change is seen</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Christiansen 1975</P>
</TD>
<TD>
<P>Well Being</P>
</TD>
<TD>
<P>5/14 on vitamin D felt better compared to 0/11 in control group</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Christiansen 1975</P>
</TD>
<TD>
<P>Bone mineral content</P>
</TD>
<TD>
<P>Vitamin D group showed significant increase in BMC as against a fall in placebo group</P>
</TD>
<TD>
<P>Influence of treatment on BMC is depicted graphically and no numerical data is available</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" NO="8">
<TITLE>Effect of thiamine on intelligence</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Parameter</P>
</TH>
<TH>
<P>Control Score</P>
</TH>
<TH>
<P>Thiamine group</P>
</TH>
<TH>
<P>p value</P>
</TH>
<TH>
<P>Remarks</P>
</TH>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Verbal IQ-Digit span</P>
</TD>
<TD>
<P>9.7</P>
</TD>
<TD>
<P>12.3</P>
</TD>
<TD>
<P>&lt;0.001</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Similarities</P>
</TD>
<TD>
<P>11.9</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>&lt;0.001</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Total verbal score</P>
</TD>
<TD>
<P>103.6</P>
</TD>
<TD>
<P>108.6</P>
</TD>
<TD>
<P>&lt;0.001</P>
</TD>
<TD>
<P>Thiamine improves neuropsychological functions related to psychomotor speed, visuospatial abilities, selective attention and verbal abstracting ability</P>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Performance IQ - Block design</P>
</TD>
<TD>
<P>9.7</P>
</TD>
<TD>
<P>11.9</P>
</TD>
<TD>
<P>&lt;0.001</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Digit symbol</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>&lt;0.001</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Botez 1993</P>
</TD>
<TD>
<P>Total performance score</P>
</TD>
<TD>
<P>100.7</P>
</TD>
<TD>
<P>105.6</P>
</TD>
<TD>
<P>&lt;0.05</P>
</TD>
<TD>
<P>Thiamine supplementation had no significant effect on information, comprehension and arithmetic, picture arrangement, picture completion or object assembly tests</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" NO="9">
<TITLE>Effect of folic acid peripheral neuropathy</TITLE>
<TABLE COLS="3" ROWS="2">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Description</P>
</TH>
<TH>
<P>Remarks</P>
</TH>
</TR>
<TR>
<TD>
<P>Horwitz 1968</P>
</TD>
<TD>
<P>No significant improvement in the mean motor conduction velocities after folic acid treatment. There was no relation between serum folate levels and severity of the neuropathy.</P>
</TD>
<TD>
<P>Mean motor conduction velocities were provided but not the standard deviation</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-09-03 10:58:35 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Effect of folic acid on overall dental hygiene</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.42665469284911" CI_START="0.3957064966321559" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.8707932315799978" LOG_CI_START="-0.40262681951326185" LOG_EFFECT_SIZE="0.23408320603336794" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.47117362943470364" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="13" WEIGHT="100.0" Z="0.7205708011542379">
<NAME>Improvement in gingival condition</NAME>
<GROUP_LABEL_1>Folic Acid Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.42665469284911" CI_START="0.3957064966321559" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.8707932315799978" LOG_CI_START="-0.40262681951326185" LOG_EFFECT_SIZE="0.23408320603336794" ORDER="53412" O_E="0.0" SE="0.7480132415430957" STUDY_ID="STD-Bowe-1971" TOTAL_1="18" TOTAL_2="13" VAR="0.5595238095238095" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.4706400472359535" CI_END="0.0808040186034758" CI_START="-0.10440224948699858" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.011799115441761395" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.9833087300042632" P_Q="0.9705675048101412" P_Z="0.802795650168171" Q="0.8952093230730196" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="38" UNITS="" WEIGHT="600.0" Z="0.24973065494722493">
<NAME>Effect of folic acid on gingival index</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.02580922679858054" CI_END="0.11412277924233143" CI_START="-0.13997287065000968" DF="1.0" EFFECT_SIZE="-0.012925045703839136" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.8723671210944172" P_Z="0.8419542454107296" STUDIES="2" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.19939439410940055">
<NAME>Gingival health index (folic acid tablets for 120 days or more)</NAME>
<CONT_DATA CI_END="0.41981935234415835" CI_START="-0.5198193523441584" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" MEAN_1="1.68" MEAN_2="1.73" ORDER="53413" SD_1="0.61" SD_2="0.45" SE="0.23970815588961505" STUDY_ID="STD-Brown-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.312614259597807"/>
<CONT_DATA CI_END="0.12196443960582729" CI_START="-0.1419644396058273" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="1.19" MEAN_2="1.2" ORDER="53414" SD_1="0.05" SD_2="0.11" SE="0.06733003292241385" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="92.68738574040219"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.11744908464710982" CI_START="-0.1974490846471099" DF="0.0" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.6185336667900393" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0" Z="0.4979295977319696">
<NAME>Gingival health index with topical solution of folic acid</NAME>
<CONT_DATA CI_END="0.11744908464710982" CI_START="-0.1974490846471099" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.16" MEAN_2="1.2" ORDER="53415" SD_1="0.11" SD_2="0.11" SE="0.08033264176742437" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6066608070910668" CI_START="-0.3666608070910668" DF="0.0" EFFECT_SIZE="0.12" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="0.6288936680078057" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0" Z="0.4832846095633818">
<NAME>Plaque index at 180 days (topical solution of folic acid)</NAME>
<CONT_DATA CI_END="0.6066608070910668" CI_START="-0.36666080709106685" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.89" MEAN_2="0.77" ORDER="53416" SD_1="0.34" SD_2="0.34" SE="0.24830089273567535" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5496214973643534" CI_END="0.4210067990859195" CI_START="-0.45861608924485114" DF="1.0" EFFECT_SIZE="-0.018804645079465818" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" NO="4" P_CHI2="0.45847248648678707" P_Z="0.9332150357086738" STUDIES="2" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="99.99999999999999" Z="0.08380051857848424">
<NAME>Plaque index after 16 weeks of treatment with folic acid tablets</NAME>
<CONT_DATA CI_END="0.6573651860822995" CI_START="-1.3973651860822998" EFFECT_SIZE="-0.3700000000000001" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="3.97" ORDER="53417" SD_1="1.24" SD_2="1.1" SE="0.5241755431150904" STUDY_ID="STD-Brown-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="18.326661646387382"/>
<CONT_DATA CI_END="0.5466608070910668" CI_START="-0.4266608070910669" EFFECT_SIZE="0.05999999999999994" ESTIMABLE="YES" MEAN_1="0.83" MEAN_2="0.77" ORDER="53418" SD_1="0.34" SD_2="0.34" SE="0.24830089273567535" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="81.6733383536126"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6775354560278568" CI_START="-0.5775354560278572" DF="0.0" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.05" NO="5" P_CHI2="1.0" P_Z="0.8759040635889849" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0" Z="0.15616360523643802">
<NAME>Pocket depth at 180 days - with folic acid tablets</NAME>
<CONT_DATA CI_END="0.6775354560278568" CI_START="-0.5775354560278572" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" MEAN_1="3.19" MEAN_2="3.14" ORDER="53419" SD_1="0.38" SD_2="0.47" SE="0.32017703436276207" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8568277089183277" CI_START="-0.4368277089183278" DF="0.0" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.06" NO="6" P_CHI2="1.0" P_Z="0.5245648239545615" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0" Z="0.6363246828768454">
<NAME>Pocket depth at 180 days - topical solution of folic acid</NAME>
<CONT_DATA CI_END="0.8568277089183277" CI_START="-0.4368277089183278" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="3.35" MEAN_2="3.14" ORDER="53420" SD_1="0.42" SD_2="0.47" SE="0.33002020140187377" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.13129209440920253" CI_END="0.24795781153567711" CI_START="-0.23107108958430453" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.008443360975686282" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.9364622786940876" P_Q="0.9638010056406499" P_Z="0.9449158870573916" Q="0.002059734626312648" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="16" UNITS="" WEIGHT="200.0" Z="0.06909263045350644">
<NAME>Hyperplasia index</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.12923235978288988" CI_END="0.26022054900935637" CI_START="-0.23999826935052976" DF="1.0" EFFECT_SIZE="0.010111139829413297" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.7192293662274963" P_Z="0.9368455443422062" STUDIES="2" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.07923520339868824">
<NAME>Hyperplasia index - 16 weeks or more treatment with folic acid tablets</NAME>
<CONT_DATA CI_END="0.5357917210998225" CI_START="-0.3757917210998224" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.92" ORDER="53421" SD_1="0.52" SD_2="0.52" SE="0.23255106965997813" STUDY_ID="STD-Brown-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="30.111139829413286"/>
<CONT_DATA CI_END="0.27917551791911904" CI_START="-0.3191755179191191" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="2.22" MEAN_2="2.24" ORDER="53422" SD_1="0.25" SD_2="0.18" SE="0.15264337522473748" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="69.88886017058671"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8217270612590394" CI_START="-0.8417270612590398" DF="0.0" EFFECT_SIZE="-0.010000000000000231" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="1.0" P_Z="0.9811995983568771" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0" Z="0.023564989956839612">
<NAME>Hyperplasia index at 180 days - folic acid topical solution</NAME>
<CONT_DATA CI_END="0.8217270612590394" CI_START="-0.8417270612590398" EFFECT_SIZE="-0.010000000000000231" ESTIMABLE="YES" MEAN_1="2.23" MEAN_2="2.24" ORDER="53423" SD_1="0.92" SD_2="0.18" SE="0.424358339142758" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Effect of folic acid on seizures</NAME>
<DICH_OUTCOME CHI2="0.13672946565398097" CI_END="2.97827751491495" CI_START="0.32353372047830065" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9816176470588236" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.473965162717997" LOG_CI_START="-0.4900804480572438" LOG_EFFECT_SIZE="-0.008057642669623458" METHOD="MH" NO="1" P_CHI2="0.7115543632911054" P_Q="0.0" P_Z="0.9738632924788695" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="38" WEIGHT="100.0" Z="0.032763365667015286">
<NAME>Folic acid on seizure frequency</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Folic Acid</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9688136207450433" CI_START="0.1562573376483175" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5986607045049133" LOG_CI_START="-0.8061595795816372" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="53424" O_E="0.0" SE="0.8251983888449983" STUDY_ID="STD-Grant-1970" TOTAL_1="23" TOTAL_2="25" VAR="0.680952380952381" WEIGHT="52.94117647058824"/>
<DICH_DATA CI_END="5.592601456845675" CI_START="0.25748303559828223" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.7476138714899108" LOG_CI_START="-0.5892513793946611" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="53425" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ralston-1970" TOTAL_1="14" TOTAL_2="13" VAR="0.6166666666666667" WEIGHT="47.05882352941176"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-09-03 10:58:35 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Effect of folic acid on AEDs</NAME>
<CONT_OUTCOME CHI2="1.2727042697759163E-34" CI_END="18.338327449922815" CI_START="-20.238327449922814" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9499999999999994" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2008-09-03 10:43:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.9230970325758574" Q="0.0" RANDOM="NO" SCALE="20.811285659486543" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="3" UNITS="" WEIGHT="100.0" Z="0.09653329404258436">
<NAME>Effect of folic acid tablet on serum phenytoin</NAME>
<GROUP_LABEL_1>Folic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.338327449922815" CI_START="-20.238327449922814" EFFECT_SIZE="-0.9499999999999993" ESTIMABLE="YES" MEAN_1="8.55" MEAN_2="9.5" ORDER="53426" SD_1="8.72" SD_2="15.65" SE="9.841164226519814" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="30.1872711111755" CI_START="-12.547271111175501" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.82" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2008-09-03 10:58:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4184946945499972" Q="0.0" RANDOM="NO" SCALE="33.865852839211094" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="3" UNITS="" WEIGHT="100.0" Z="0.8090355691046528">
<NAME>Effect of folic acid topical solution on serum phenytoin</NAME>
<GROUP_LABEL_1>Folic acid Solution</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="30.1872711111755" CI_START="-12.547271111175501" EFFECT_SIZE="8.82" ESTIMABLE="YES" MEAN_1="18.32" MEAN_2="9.5" ORDER="53427" SD_1="13.64" SD_2="15.65" SE="10.901869258679143" STUDY_ID="STD-Drew-1987" TOTAL_1="5" TOTAL_2="3" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Effect of vitamin D</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.7170091484041965" CI_START="2.48299085159582" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.6000000000000085" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.671168342024645E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="110" UNITS="" WEIGHT="100.00000000000001" Z="6.316752512210449">
<NAME>Vitamin D on bone mineral content</NAME>
<GROUP_LABEL_1>Vitamin D</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vitamin D</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.7170091484041965" CI_START="2.48299085159582" EFFECT_SIZE="3.6000000000000085" ESTIMABLE="YES" MEAN_1="103.7" MEAN_2="100.1" ORDER="53428" SD_1="4.9" SD_2="3.6" SE="0.5699130990237647" STUDY_ID="STD-Christiansen-1973a" TOTAL_1="116" TOTAL_2="110" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Improvement in well-being</NAME>
<GROUP_LABEL_1>Vitamin D</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vitamin D</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2934436343631255" CI_START="0.34290519101436273" EFFECT_SIZE="0.6659793814432989" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.11174750779671802" LOG_CI_START="-0.46482594033903957" LOG_EFFECT_SIZE="-0.1765392162711608" ORDER="53429" O_E="0.0" SE="0.33868209751954237" STUDY_ID="STD-Christiansen-1973a" TOTAL_1="116" TOTAL_2="110" VAR="0.11470556318023682" WEIGHT="0.0"/>
<DICH_DATA CI_END="272.8292073103759" CI_START="0.6498946760702473" EFFECT_SIZE="13.31578947368421" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.4358908611997623" LOG_CI_START="-0.1871570207537845" LOG_EFFECT_SIZE="1.124366920222989" ORDER="53430" O_E="0.0" SE="1.5407913101559372" STUDY_ID="STD-Christiansen-1975" TOTAL_1="14" TOTAL_2="11" VAR="2.374037861452049" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-09-03 10:44:02 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Effect of vitamin E</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="130.9147459983073" CI_START="5.456907590785663" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="26.728068975964955" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="2.1169885674446296" LOG_CI_START="0.7369465993481683" LOG_EFFECT_SIZE="1.426967583396399" METHOD="PETO" MODIFIED="2008-09-03 10:44:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="5.051801239593284E-5" Q="0.0" RANDOM="NO" SCALE="161.49528230241512" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="4.053217416888888">
<NAME>Vitamin E on seizure frequency</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="130.9147459983073" CI_START="5.456907590785663" EFFECT_SIZE="26.728068975964955" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.1169885674446296" LOG_CI_START="0.7369465993481683" LOG_EFFECT_SIZE="1.426967583396399" ORDER="53431" O_E="5.0" SE="0.8106434833777776" STUDY_ID="STD-Ogunmekan-1989" TOTAL_1="12" TOTAL_2="12" VAR="1.5217391304347825" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-08-04 14:49:40 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-08-04 14:49:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-04 14:45:12 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-04 14:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor Epilepsy explode all trees<BR/>#2 (epilep*)<BR/>#3 MeSH descriptor Seizures explode all trees<BR/>#4 (seizure*)<BR/>#5 (convulsion*)<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Vitamins explode all trees<BR/>#8 (vitamin*)<BR/>#9 (retinol)<BR/>#10 (thiamin*)<BR/>#11 (riboflavin*)<BR/>#12 (niacin)<BR/>#13 (pyridox*)<BR/>#14 "pantothenic acid"<BR/>#15 (cyanocobalamin)<BR/>#16 (cobalamin)<BR/>#17 "folic acid"<BR/>#18 "ascorbic acid"<BR/>#19 (ergosterol)<BR/>#20 (calcitriol)<BR/>#21 (cholecalciferol)<BR/>#22 (tocopherol)<BR/>#23 (menadione)<BR/>#24 "Vitamin U" OR "vitamin U"<BR/>#25 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)<BR/>#26 (#6 AND #25)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-08-04 14:49:40 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-10-17 16:51:40 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-17 16:52:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. exp EPILEPSY/</P>
<P>2. epilep$.tw.</P>
<P>3. exp SEIZURES/</P>
<P>4. seizure$.tw.</P>
<P>5. exp CONVULSIONS/</P>
<P>6. convulsion$.tw.</P>
<P>7. exp "growth substances, pigments, and vitamins"/</P>
<P>8. exp VITAMINS/</P>
<P>9. vitamin$.tw.</P>
<P>10. retinol.tw.</P>
<P>11. (thiamin or thiamine).tw.</P>
<P>12. (riboflavin or riboflavine).tw.</P>
<P>13. niacin.tw.</P>
<P>14. pyridox$.tw.</P>
<P>15. (pantothenic and acid).tw.</P>
<P>16. cyanocobalamin.tw.</P>
<P>17. cobalamin.tw.</P>
<P>18. (folic and acid).tw.</P>
<P>19. (ascorbic and acid).tw.</P>
<P>20. ergosterol.tw.</P>
<P>21. calcitriol.tw.</P>
<P>22. cholecalciferol.tw.</P>
<P>23. tocopherol.tw.</P>
<P>24. menadione.tw.</P>
<P>25. ("vitamin U" or "Vitamin U").tw.</P>
<P>26. 1 or 2 or 3 or 4 or 5 or 6</P>
<P>27. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25</P>
<P>28. 26 and 27</P>
<P>29. randomized controlled trial.pt.</P>
<P>30. controlled clinical trial.pt.</P>
<P>31. exp Randomized Controlled Trials/</P>
<P>32. exp Random Allocation/</P>
<P>33. exp Double-Blind Method/</P>
<P>34. exp Single-Blind Method/</P>
<P>35. 29 or 30 or 31 or 32 or 33 or 34</P>
<P>36. 35 and 28</P>
<P>37. (animal not human).sh.</P>
<P>38. 36 not 37</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>